Bi­o­log­ics are no longer a race of speed alone. Nowa­days, suc­cess for bio­phar­ma com­pa­nies means mas­ter­ing com­plex­i­ty, con­trol­ling costs, and up­hold­ing un­com­pro­mis­ing qual­i­ty all at once.

Re­zon Bio was cre­at­ed to thrive in this en­vi­ron­ment. With over a decade of bio­man­u­fac­tur­ing ex­per­tise and 90 years of phar­ma­ceu­ti­cal her­itage, Re­zon Bio is a new Eu­ro­pean bi­o­log­ics CD­MO built for the next era. By com­bin­ing proven sci­en­tif­ic ex­per­tise with the agili­ty of a mod­ern part­ner, Re­zon Bio de­liv­ers so­lu­tions that are smarter, faster and more cost-ef­fi­cient, bring­ing ex­cel­lence and val­ue to every stage of de­vel­op­ment.

Re­zon Bio’s sto­ry is one of trans­for­ma­tion and con­ti­nu­ity. Its foun­da­tions lie in the lega­cy of Pol­phar­ma, a com­pa­ny that has shaped the Pol­ish phar­ma­ceu­ti­cal in­dus­try since 1935. Rec­og­niz­ing the grow­ing im­por­tance of bi­o­log­ics, Pol­phar­ma ini­ti­at­ed its in­vest­ment in these modal­i­ties near­ly 15 years ago, lay­ing the ground­work for ad­vanced R&D and man­u­fac­tur­ing ca­pa­bil­i­ties in this com­plex field. As the bi­o­log­ics di­vi­sion ma­tured, Pol­phar­ma Bi­o­log­ics was es­tab­lished as a ded­i­cat­ed or­ga­ni­za­tion fo­cused on the de­vel­op­ment of biosim­i­lars, ad­vanc­ing mul­ti­ple pro­grams to­ward glob­al com­mer­cial­iza­tion. Over the last decade, this team has built world-class ca­pa­bil­i­ties from an­a­lyt­i­cal and process de­vel­op­ment to com­mer­cial-scale GMP man­u­fac­tur­ing and achieved key mile­stones in­clud­ing suc­cess­ful FDA, EMA, and MHRA in­spec­tions.

In 2025, Re­zon Bio was es­tab­lished as an in­de­pen­dent bi­o­log­ics CD­MO head­quar­tered in Poland, fo­cused sole­ly on pro­vid­ing end-to-end ser­vices for bio­phar­ma and biotech com­pa­nies. The com­pa­ny’s two state-of-the-art fa­cil­i­ties in Gdańsk and Duch­nice-War­saw now form a pow­er­ful dual-site plat­form of­fer­ing flex­i­bil­i­ty, scal­a­bil­i­ty and reg­u­la­to­ry readi­ness.

The CD­MOs that tru­ly un­der­stand their clients are those that have faced the same chal­lenges them­selves. The com­pa­ny’s jour­ney through the de­mand­ing world of biosim­i­lar de­vel­op­ment shaped that un­der­stand­ing. Teach­ing its teams how to nav­i­gate com­plex­i­ty, bal­ance pre­ci­sion with speed and up­hold the high­est stan­dards un­der pres­sure. This ex­pe­ri­ence un­der­pins Re­zon Bio’s prag­mat­ic, ef­fi­cien­cy-dri­ven CD­MO mod­el, en­abling clients to min­i­mize risk, avoid cost­ly de­lays and reach the mar­ket faster.

As sup­ply chains re­bal­ance glob­al­ly, Eu­rope is be­com­ing a key hub for bi­o­log­ics man­u­fac­tur­ing. With­in this land­scape, Pol­land of­fers a unique com­pet­i­tive ad­van­tage, a com­bi­na­tion of un­com­pro­mised qual­i­ty, cost-ef­fi­cien­cy and reg­u­la­to­ry ex­cel­lence.

Re­zon Bio lever­ages this po­si­tion to pro­vide clients around the world with high-qual­i­ty, cost-com­pet­i­tive bi­o­log­ics man­u­fac­tur­ing with­in the Eu­ro­pean reg­u­la­to­ry frame­work. Its in­te­grat­ed ser­vices cov­er the en­tire de­vel­op­ment and man­u­fac­tur­ing jour­ney, in­clud­ing:

• An­a­lyt­i­cal and process de­vel­op­ment us­ing mod­ern, sin­gle-use sys­tems and in­stru­men­ta­tion, in­clud­ing Sar­to­rius’ AM­BR® high-through­put biore­ac­tor tech­nol­o­gy
• Clin­i­cal and com­mer­cial man­u­fac­tur­ing across two com­ple­men­tary sites
• Com­pre­hen­sive qual­i­ty and reg­u­la­to­ry sup­port for glob­al sub­mis­sions and au­dits

Each project is guid­ed by a mul­ti-dis­ci­pli­nary team who com­bines deep tech­ni­cal ex­per­tise with com­mer­cial ex­pe­ri­ence from glob­al prod­uct launch­es. Di­rect ac­cess to lead­er­ship and se­nior sci­en­tists en­sures fast de­ci­sion-mak­ing, clear com­mu­ni­ca­tion and tai­lored client sup­port.

Re­zon Bio op­er­ates two state-of-the-art sites with ca­pa­bil­i­ties de­signed to take bi­o­log­ic pro­grams from con­cept to com­mer­cial­iza­tion with speed and con­fi­dence.

The Gdańsk fa­cil­i­ty serves as the com­pa­ny’s in­no­va­tion and de­vel­op­ment cen­ter, ded­i­cat­ed to ear­ly- and mid-stage projects. Ful­ly equipped with sin­gle-use biore­ac­tors, the fa­cil­i­ty sup­ports process de­vel­op­ment and char­ac­ter­i­za­tion and clin­i­cal man­u­fac­tur­ing for both mi­cro­bial and mam­malian sys­tems.

The Duch­nice-War­saw site com­ple­ments this with late-stage and com­mer­cial man­u­fac­tur­ing ca­pa­bil­i­ties. It fea­tures two sin­gle-use man­u­fac­tur­ing lines cen­tered on 2,000-liter biore­ac­tors,  with room for fur­ther ex­pan­sion. Stain­less-steel buffer and me­dia prepa­ra­tion sys­tems en­hance ef­fi­cien­cy and cost con­trol.

To­geth­er, the two sites form a uni­fied plat­form that en­sures smooth tran­si­tions be­tween de­vel­op­ment stages, min­i­miz­ing tech trans­fer risks, ac­cel­er­at­ing time­lines and en­sur­ing con­sis­tent qual­i­ty from pi­lot to full-scale com­mer­cial pro­duc­tion.

At Re­zon Bio, peo­ple are the true dif­fer­en­tia­tor. Many team mem­bers helped build Poland’s bio­man­u­fac­tur­ing sec­tor form the ground up, bring­ing to­geth­er the best of big phar­ma ex­pe­ri­ence and the en­tre­pre­neur­ial dri­ve of a fast-grow­ing biotech ecosys­tem. Oth­ers re­turned to Poland af­ter years abroad, drawn by a cul­ture that val­ues au­ton­o­my, ac­count­abil­i­ty and pur­pose.

This col­lec­tive ex­per­tise forms the foun­da­tion of Re­zon Bio’s guid­ing phi­los­o­phy: where ded­i­ca­tion de­liv­ers. Every client works di­rect­ly with ex­perts who take own­er­ship of re­sults, com­mu­ni­cate trans­par­ent­ly and ap­proach each mol­e­cule not as a project, but as a shared mis­sion to bring ther­a­pies to pa­tients faster and more re­li­ably.

Re­zon Bio’s ef­fi­cien­cy is pow­ered by both ex­pe­ri­ence and tech­nol­o­gy. The com­pa­ny in­te­grates dig­i­tal tools and AI-sup­port­ed sys­tems across op­er­a­tions to stream­line work­flows, iden­ti­fy pat­terns and op­ti­mize re­al-time de­ci­sion-mak­ing.

From au­to­mat­ed doc­u­men­ta­tion and da­ta an­a­lyt­ics to pre­dic­tive mod­el­ing and process op­ti­miza­tion, these tech­nolo­gies re­duce com­plex­i­ty and ac­cel­er­ate de­liv­ery, all while main­tain­ing hu­man over­sight. For Re­zon Bio, in­no­va­tion is not about adopt­ing the lat­est tech­nol­o­gy, but about ap­ply­ing the right tools to de­liv­er mea­sur­able im­prove­ments in re­li­a­bil­i­ty, speed, and cost-ef­fi­cien­cy, en­sur­ing every process de­liv­ers tan­gi­ble val­ue for clients.

Re­zon Bio’s mis­sion is clear: to be the trust­ed Eu­ro­pean CD­MO part­ner for small and mid-sized bio­phar­ma and biotech com­pa­nies seek­ing both agili­ty and ex­cel­lence. While larg­er ser­vice providers of­ten pri­or­i­tize scale, Re­zon Bio fo­cus­es on part­ner­ship, of­fer­ing tai­lored so­lu­tions, trans­par­ent col­lab­o­ra­tion and com­mu­ni­ca­tion and a shared com­mit­ment to suc­cess.

Look­ing ahead the com­pa­ny plans to ex­pand its ca­pac­i­ty, en­hance dig­i­tal in­fra­struc­ture and ex­plore new modal­i­ties across bi­o­log­ics and ad­vanced ther­a­pies. Yet its guid­ing prin­ci­ple re­mains the same: com­bin­ing sci­en­tif­ic ex­cel­lence with op­er­a­tional prag­ma­tism to help clients de­liv­er ther­a­pies bet­ter, faster and cost-ef­fec­tive­ly.

In a sec­tor de­fined by in­no­va­tion and trust, Re­zon Bio is ded­i­cat­ed to de­liv­er­ing both in every part­ner­ship.

Learn more about Re­zon Bio here.